Nasdaq

Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements

TOKYO, Nov 20, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" ...
Medscape

NICE Recommends Once Daily Tablet for Advanced Breast Cancer

More than a thousand people in England with a specific type of advanced breast cancer could benefit from a new once-a-day tablet following a decision by the National Institute for Health and Care ...
Hosted on MSN

NHS bladder cancer tablet to be rolled out across England - full details

A tablet for the most common form of bladder cancer has been given the green light for use by the NHS. The recommendation on erdafitinib by the National Institute of Health and Care Excellence (Nice) ...
Nasdaq

Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements

TOKYO, Sept 24, 2024 - (JCN Newswire) - - Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements ...